NMI promotes cell proliferation through TGFβ/Smad pathway by upregulating STAT1 in colorectal cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Colorectal cancer (CRC) remains a significant global health challenge with incompletely understood mechanisms.
• The role of N-myc interactor (NMI) as an oncogene or tumor suppressor varies across cancer types, with its specific function in CRC needing further clarification.

Purpose of the Study:

• To investigate the role of N-myc interactor (NMI) in colorectal cancer (CRC) progression.
• To elucidate the molecular mechanisms by which NMI influences CRC cell proliferation.
• To evaluate the prognostic value of NMI expression in CRC patients.

Main Methods:

• Quantitative analysis of NMI expression in CRC tissues and cells.
• In vitro studies involving NMI gene silencing and overexpression in CRC cells.
• Flow cytometry to assess cell cycle progression.
• Western blot analysis to examine protein phosphorylation and expression (STAT1, Smad3).
• Pharmacological inhibition of the TGFβ/Smad pathway using SIS3.

Main Results:

• NMI expression was significantly elevated in CRC tissues and cells compared to normal controls.
• NMI overexpression promoted CRC cell proliferation, while NMI silencing suppressed it.
• NMI facilitates G1 to S phase transition, driving cell cycle progression.
• NMI upregulates STAT1 expression, leading to suppressed Smad3 phosphorylation.
• Inhibition of the TGFβ/Smad pathway with SIS3 reversed the proliferative effects of NMI depletion.

Conclusions:

• N-myc interactor (NMI) acts as an oncogene in colorectal cancer, promoting cell proliferation.
• NMI drives CRC progression through the TGFβ/Smad signaling pathway, involving STAT1.
• NMI expression levels can serve as a prognostic biomarker for colorectal cancer patients.